What is Olyte-E?
Olyte-E is the chemical name for salt. Olyte-E can reduce some types of bacteria in certain body secretions, such as saliva.
Olyte-E inhalation is used to produce sputum (mucus, or phlegm) from the mouth to help improve lung function in people with cystic fibrosis, or to collect sputum for medical testing. This medication may also be used to dilute other medications inhaled through a nebulizer.
Olyte-E inhalation may also be used for other purposes not listed in this medication guide.
Olyte-E indications
Airlife Modudose Olyte-E as isotonic solution: the dehydration of various origins. To maintain the volume of blood plasma during and after surgery. As a solvent for various drugs.
Hypertonic solution: violations of water-electrolyte metabolism: lack of sodium and chlorine ions; hypoosmotic dehydration of various origins (due to prolonged vomiting, diarrhea, burns with a gastric fistula, pulmonary hemorrhage, intestinal bleeding).
Eye drops and ointment: irritation of the cornea with inflammatory and allergic diseases (combined therapy).
How should I use Olyte-E?
Use Olyte-E nebulizer solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Olyte-E nebulizer solution is for inhalation in a nebulizer only. Do not take Olyte-E nebulizer solution by mouth or inject it.
- Olyte-E nebulizer solution is used to dilute other medicines. Follow the instructions provided by your doctor.
- Olyte-E nebulizer solution may come in a single-dose vial or in a container with multiple doses. Be sure to use the proper amount of Olyte-E nebulizer solution. If you are using Olyte-E nebulizer solution from a multiple-dose container, use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you are using a vial, use your dose immediately after opening the vial and throw away any unused medicine. Do not save the contents of an opened vial for later use.
- Do not use Olyte-E nebulizer solution if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- This product is intended to dilute other medicines for use in a nebulizer. If you miss a dose of your medicine, follow the missed dose instructions for the medicine that you are mixing with this product.
Ask your health care provider any questions you may have about how to use Olyte-E nebulizer solution.
Uses of Olyte-E in details
This product is used to treat dryness inside the nose (nasal passages). It helps add moisture inside the nose to dissolve and soften thick or crusty mucus. In babies and young children with stuffy noses who cannot blow their noses, using this product helps to make the mucus easier to remove with a nasal bulb syringe. This helps relieve stuffiness and makes breathing easier.
This product contains a purified gentle salt solution (also called saline or Olyte-E solution). It does not contain any medication.
How to use Olyte-E nasal
Spray this product into each nostril as needed or as directed by your doctor. This product may also be given into the nose as drops or a stream. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.
Try not to touch the container tip to the inside of your nose. If this happens, rinse the tip with hot water and dry with a clean tissue before recapping the container.
If your condition persists or worsens, or if you think you may have a serious medical problem, seek immediate medical attention.
Olyte-E description
Olyte-E, also known as salt, common salt, table salt or halite, is an ionic compound with the chemical formula NaCl, representing a 1:1 ratio of sodium and chloride ions. Olyte-E is the salt most responsible for the salinity of seawater and of the extracellular fluid of many multicellular organisms. It is listed on the World Health Organization Model List of Essential Medicines.
Olyte-E dosage
All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment.
As directed by a physician. Dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition, concomitant treatment, and on the patient’s clinical and laboratory response to treatment.
When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.
Do not administer unless the solution is clear and seal is intact.
Additives may be incompatible with Olyte-E Injection, USP. As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Olyte-E Injection, USP is appropriate. After addition, check for unexpected color changes and/or the appearance of precipitates, insoluble complexes or crystals.
The instructions for use of the medication to be added and other relevant literature must be consulted. Additives known or determined to be incompatible must not be used. When introducing additives to Olyte-E Injection, USP, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.
After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. Discard any unused portion.
Olyte-E interactions
See also:
What other drugs will affect Olyte-E?
Caution must be exercised in the administration of Olyte-E Injection, USP to patients receiving corticosteroids or corticotropin.
Studies have not been conducted to evaluate additional drug/drug or drug/food interactions with Olyte-E (Olyte-E (Olyte-E injection) injection) Injection, USP.
Olyte-E side effects
See also:
What are the possible side effects of Olyte-E?
Post-Marketing Adverse Reactions
The following adverse reactions have been identified during postapproval use of Olyte-E Injection, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported in the post-marketing experience during use of 0.9% Olyte-E Injection, USP and include the following:
hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus.
Also reported are infusion site reactions, such as infusion site erythema, injection site streaking, burning sensation, and infusion site urticaria.
The following adverse reactions have not been reported with 0.9% Olyte-E Injection, USP but may occur: hypernatremia, hyperchloremic metabolic acidosis, and hyponatremia, which may be symptomatic.
Hyponatremia has been reported for 0.45% Olyte-E Injection, USP.
The following adverse reactions have not been reported with 0.45% Olyte-E Injection, USP but may occur: hyperchloremic metabolic acidosis, hypersensitivity/infusion reactions (including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus), and infusion site reactions (such as infusion site erythema, injection site streaking, burning sensation, infusion site urticaria).
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Olyte-E contraindications
See also:
What is the most important information I should know about Olyte-E?
Due to potential toxicity of benzyl alcohol in newborns, Bacteriostatic Olyte-E Injection, USP, 0.9% containing benzyl alcohol must not be used in this patient population.
Bacteriostatic Olyte-E Injection, USP, 0.9% should not be used for fluid or Olyte-E replacement.
Active ingredient matches for Olyte-E:
Sodium Chloride in India.
Anhydrous dextrose/potassium chloride/sodium citrate in India.
| Unit description / dosage (Manufacturer) | Price, USD |
| Olyte-E sodium chloride 2.6 g, potassium chloride 1.5 g, Sodium citrate 2.9 g, anhydrous dextrose 13.5 g. POWD / 21.80 | $ 0.20 |
List of Olyte-E substitutes (brand and generic names): | |
| Olynth Salin (Germany) | |
| Spray; Nasal; Sodium Chloride (Pfizer consumer) | |
| Omni-Sorb (Germany) | |
| Optic Saline 5% (Egypt) | |
| Opticlear | |
| Liquid; Ophthalmic; Sodium Chloride 0.44% | |
| Opticlear solution/ drops .5 mg/mL (Major Pharmaceuticals (US)) | |
| Optics Laboratory Ocufresh | |
| Solution; Ophthalmic; Sodium Chloride 0.9% | |
| ORFIX POWD (India) | |
| ORS L | |
| ORS L 200 ml Solution (Juggat Pharma) | $ 0.27 |
| Ors-L Plus (India) | |
| Ors-L Plus Sodium chloride 250 mg, potassium chloride 300 mg, sodium citrate 580 mg, dextrose 5.4 g, taurine 100mg, calcium lactate 80 mg, magnesium sulphate 100 mg, carbohydrates 24 g. O-LIQD / 200ml (J & J) | $ 0.27 |
| ORS-L PLUS oral liqd 200ml (J & J) | $ 0.27 |
| OSMOEYE (India) | |
| OSMOEYE eye oint 6 % w/w x 3g (Eyekare) | $ 1.57 |
| Osmoeye 5% w/v Eye Drop (Eyekare) | $ 0.51 |
| Osmoeye 6% w/v Eye Ointment (Eyekare) | $ 1.57 |
| Osmoeye 5% w/v Gel (Eyekare) | $ 0.51 |
| Osolin (India) | |
| Osolin 0.65% w/v N-DPS / 15ml (Olcare (Fusion)) | $ 0.27 |
| OSOLIN nasal drops 0.65 % w/v x 15ml (Olcare (Fusion)) | $ 0.27 |
| Otricare-S (India) | |
| Otricare-S 0.65% w/v N-DPS / 20ml (Biotabs) | $ 0.34 |
| OTRICARE-S nasal drops 0.65 % w/v x 20ml (Biotabs) | $ 0.34 |
| OTRINOZ -S | |
| OTRINOZ -S 0.74% NASAL DROPS 1 packet / 10 ML nasal drops each (Novartis India Ltd) | $ 0.43 |
| OTRINOZ S | |
| Otrisal (New Zealand) | |
| Otrisalin (Greece, Turkey) | |
| Otrivin 0.74% Baby (Egypt) | |
| Otrivin Baby (Italy) | |
| Otrivin S | |
| Otrivin S Nasal 10 ml Drop (Novartis India Ltd) | $ 0.33 |
| Otrivin S 0.74% w/v Nasal Spray (Novartis India Ltd) | $ 0.53 |
| Otrivin saline baby (Australia) | |
| Otrivin Sea Water (Australia) | |
| OTRIVIN-S (India) | |
| 0.74 % w/v x 10ml (Novartis (OTC)) | $ 0.30 |
| Otrivin-S 0.74% w/v N-DPS / 10ml (Novartis (OTC)) | $ 0.30 |
| OTRIVIN-S nasal spray 0.74 % w/v x 10ml (Novartis (OTC)) | $ 0.45 |
| Otrivin-S 0.74% w/v N-DPS / 10ml (Novartis (OTC)) | $ 0.30 |
| Otrivini (Israel) | |
| Spray; Nasal; Sodium Chloride 0.74% (Novartis consumer) | |
| Otrivini Saline for Babies | |
| Spray; Nasal; Sodium Chloride 0.74% | |
| Otsu-NS (Indonesia) | |
| Otsu-NS 100 mL x 1's (Otsuka) | |
| Otsu-NS 250 mL x 1's (Otsuka) | |
| Otsu-NS 500 mL x 1's (Otsuka) | |
| Otsu-NS 1 L x 1's (Otsuka) | |
| PD-LYTE-E (India) | |
| 500ml (Parenteral Drugs) | $ 0.43 |
| Pd-Lyte-E Sodium chloride 0.5 g, anhydrous dextrose 5 g, magnesium chloride 0.031 g, potassium chloride 0.075 g, calcium chloride 0.052 g, sodium metabisulphite 0.02 g, sodium acetate 0.64 g, sodiumcitrate 0.075 g/100 mL. INF / 500ml (Parenteral Drugs) | $ 0.43 |
| PD-LYTE-E infusion 500ml (Parenteral Drugs) | $ 0.43 |
| Pd-Lyte-E Sodium chloride 0.5 g, anhydrous dextrose 5 g, magnesium chloride 0.031 g, potassium chloride 0.075 g, calcium chloride 0.052 g, sodium metabisulphite 0.02 g, sodium acetate 0.64 g, sodiumcitrate 0.075 g/100 mL. INF / 500ml (Parenteral Drugs) | $ 0.43 |
See 1613 substitutes for Olyte-E | |
References
- DailyMed. "SODIUM CITRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Sodium citrate". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Olyte-E are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Olyte-E. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Olyte-E before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Olyte-E. To get the time effectiveness of using Olyte-E drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 day | 1 | 100.0% | |
1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
